RR-MS, remitting-relapsing multiple sclerosis
An Atypical Presentation of Multiple Sclerosis
... of Multiple Sclerosis: There are four categories of disease described: relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis ...
5
Intrathecal IgG synthesis in relapsing remitting multiple sclerosis (MS) is decreased by natural human alpha interferon
... We report a significant decrease of IT IgG synthesis at 12 weeks of natural human IFN-alpha (IFN-α): therapy in RRMS. Although not reaching significance, values at 26 weeks, 2 weeks after stopping drug, values were much ...
5
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
... from RR-MS patients are substan- tially reduced compared with healthy controls ...for RR-MS patients, where the activity was already substantially lower at early ages ...in RR-MS ...
8
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
... of MS, such as in patients with clinically iso- lated demyelinating syndromes or RRMS [1, ...the MS disease course, and serve to offset or mask on- going volume loss due to atrophy ...
8
Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis
... Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system (CNS) through demyelination and neurodegen- ...in MS patients have been investigated independently ...
5
Association of Human Herpesvirus 6 and 8 in Relapsing Remitting Multiple Sclerosis Type during Exacerbation
... Above all, we used nested PCR (nPCR) to investigate the genomic DNA of HHV-6 and PCR for HHV-8 in peripheral blood mononuclear cells (PBMC) samples of 20 relapsing-remitting MS (RRMS) patients during ...
5
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosisThe MIRROR study
... Overall, this study demonstrates that ofatumumab has a high capacity to suppress new brain MRI lesions with subcutaneous administration at considerably lower (and incompletely B-cell depleting) doses compared with those ...
19
Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
... in MS in numerous studies ...in MS lesions [24] and is increased in CSF from MS patients ...mixed MS group and a non-inflammatory control group [29], reported increased IL10 mRNA expression in ...
12
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
... (Tysabri Outreach Unified Commitment to Health), which aimed to ensure that only prescribers and patients enrolled in TOUCH could prescribe or receive Tysabri. Eight years after licensing of natalizumab, considerable ...
9
Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption
... pathological MS patterns, depending on the relative prevalence of inflammation, demyelination, oligodendro- cytes and remyelination ...to relapsing-remitting MS (RRMS) [13] and retrobulbar ...
7
Disease-modifying therapies in relapsing–remitting multiple sclerosis
... It has been hypothesized that the efficacy of IFN could be higher if it is used at the first appearance of symptoms, in Clinically Isolated Syndromes suggestive of demyelinating events, a pathology which carries a high ...
9
Biomarkers of multiple sclerosis: current findings
... Multiple sclerosis (MS) is a chronic autoimmune-mediated demyelinating disease of the central nervous system (CNS) that is usually associated with varying degrees of progressive ...as ...
11
Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis
... with relapsing-remitting multiple sclerosis (RRMS), and the most commonly- used drugs as ...with MS, the pro-inflammatory role of disease-modifying drugs, especially INF-β, could affect ...
8
An update of teriflunomide for treatment of multiple sclerosis
... in MS in a phase II, multicenter, randomized, placebo-controlled, and double-blind trial that consisted of 179 relapsing MS patients (relapsing–remitting MS [RRMS] or progressive ...
14
Defective structural RNA processing in relapsing remitting multiple sclerosis
... Ro60 and La proteins are components of ribonucleopro- tein particles, bind discrete structural ncRNAs, and are thought to play important roles in ncRNA processing and quality control. For these reasons, we measured ...
13
The clinical potential of blood-proteomics in multiple sclerosis
... to MS diagnosis may be more appropriate. Consequently, the MS-patient is diagnosed by pathophysiological evaluation of clinical or paraclinical dissemination in time and space [8-10], and the only ...
8
Predictive Value of Lesions for Relapses in Relapsing remitting Multiple Sclerosis
... of relapsing-remitting multiple sclerosis and secondary progressive multiple scle- rosis after standard therapeutic doses are adminis- tered for a period of $ 1 year (5, 16, ...
8
Functional cortical changes in relapsing-remitting multiple sclerosis at amplitude configuration: a resting-state fMRI study
... Multiple sclerosis (MS) is a neurodegenerative disorder that is characterized by motor dysfunction and disseminated axonal degeneration as well as inflammatory demyelina- tion in the central nervous ...
9
Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study
... Methods: The PubMed, Embase, and Web of Science databases were systematically searched for relevant studies. Articles in English that evaluated the utility of NFL in CSF and blood in the diagnosis of MS were ...
14
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
... complexity and influenced by the attitude towards risk on the part of both the patient and the clinical team. The larger the MS drug market becomes, the harder it will be for clinicians to help patients decide on ...
22